A to Z / Repair & recovery

ARA-290

Also known as cibinetide, Helix B surface peptide.

Best known for The neuropathic pain peptide with human trial data

Evidence★★★☆☆

Safety dataPoorly characterised

Route Injectable (subcutaneous)

United StatesInvestigational

AustraliaNot listed by name; unapproved therapeutic good

as at 16 September 2026

What it is

ARA-290 (cibinetide) is an 11-amino-acid peptide derived from a region of erythropoietin (EPO). It is an investigational compound that has reached small randomised human trials. It was engineered to retain EPO's tissue-protective effects while removing its effect on red blood cell production entirely.

What the full entry covers

The book carries the rest of this entry:

Where the research stands, with every claim cited
What people commonly ask, and what the research shows so far
Dosing in four labelled bands, described and not recommended
Side effects, serious risks, cautions and interactions
Questions to discuss with your doctor
How it compares with BPC-157, KPV, LL-37

Related entries

BPC-157Tendon, joint and gut repair · Evidence ★★☆☆☆
KPVThe gut and inflammation peptide with a rising profile · Evidence ★☆☆☆☆
LL-37The body's own antimicrobial peptide, discussed for chronic infection · Evidence ★☆☆☆☆

A certificate of analysis tells you what is in a vial. The evidence rating above tells you whether the compound has been shown to work in humans. Neither answers the other's question. How to read a certificate of analysis.

This page describes what is known and not known about ARA-290. It is not medical advice and not a recommendation to use it.